Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL)

TrackMagicFormul (76.06) Submitted: 5/15/2013 6:52:28 AM : Start Price: $15.34 AUXL Score: -2.98

Investors should consider selling puts. You can achieve some very high annualized returns at strikes significantly below the current price. e.g.

Dec 13 $15.00 strike at $2.00 has 15% discount and 22% annualized return.

zzlangerhans (99.77) Submitted: 1/29/2013 6:16:18 PM : Start Price: $18.18 AUXL Score: -28.12

I keep toying with the idea of buying Auxilium and I'm always glad I didn't. The company rode testosterone supplement Testim to huge gains in the middle part of the last decade and navigated the financial crisis without too much damage. Over the last few years, the stock has lost its luster over concerns of generic competition for Testim and the apparent weakness of Xiaflex as a successor.

This year, the share price did spike nicely from the current level on some optimism on Xiaflex but the momentum was not sustained in the context of more weak revenue numbers for Testim and Xiaflex. I had to close my prior outperform with a large negative score but I'm willing to give it another stab at this level. I think the most likely source of a rebound is positive sentiment regarding the new indication of Xiaflex for cellulite.

Live by the sword and die by the sword. I'm cocky regarding the stocks I've done well with, so I try to be humble regarding the ones that have kicked my ass. I'd say I'm only 60% likely to close this pick with a positive score, so this might be one of the ZZ picks to ignore.

portefeuille (99.78) Submitted: 12/15/2011 9:36:10 PM : Start Price: $13.90 AUXL Score: -37.35

There are currently 100 AUXL shares in my "fund" with break-even of around 18.86 USD.
http://caps.fool.com/Blogs/fund-trades/678775.

21popsontop (< 20) Submitted: 11/24/2010 5:39:07 AM : Start Price: $19.70 AUXL Score: -63.62

Drug dealers with a license.

Ikeydoc (< 20) Submitted: 7/4/2009 11:40:46 AM : Start Price: $29.95 AUXL Score: -138.40

Release of treatment for Dupuytrens Disease

greenwave3 (47.88) Submitted: 8/27/2008 12:18:19 AM : Start Price: $39.79 AUXL Score: +97.25

Nice products, too much hype. How can you justify a market cap of $1.6 Billion with sales of under $100 Million? Some claim 20% annual sales growth. Even assuming they're correct, this one needs to be chopped in half before we even start to think about a fair valuation.

bernies1 (< 20) Submitted: 3/24/2008 8:18:56 PM : Start Price: $26.47 AUXL Score: -71.39

good stock

supez2004 (50.87) Submitted: 3/3/2008 1:08:22 AM : Start Price: $32.04 AUXL Score: -83.61

Xiaflex has potential to be a blockbuster drug in a niche market without many competitors ...

datasource (< 20) Submitted: 2/25/2008 4:06:07 PM : Start Price: $33.22 AUXL Score: +81.84

Overepriced with negative earnings for the foreseable future.

Also is currently a one-product company with mixed results in the whole synthetic testosterone marketplace. There are negative stories in the print press regarding the effectiveness of such products, including at least one that suggests that treatments can have the opposite of the desired effect.

NVR2LATE4MONEY (< 20) Submitted: 12/6/2007 4:02:19 PM : Start Price: $28.25 AUXL Score: -62.11

Auxl has a hot pipeline

htbrennan (45.34) Submitted: 8/9/2007 12:03:28 PM : Start Price: $22.53 AUXL Score: -51.93

CEO is a marketer,Exec. VP, Medimmune, rather than a Doc. Already have product and in late stage with new, so marketing is important.

mblin13 (62.75) Submitted: 3/1/2007 12:57:53 PM : Start Price: $12.32 AUXL Score: -3.28

downside provided by testim;
other drugs in phase 3 trials;
stock could triple

hlacheen (99.41) Submitted: 2/14/2007 12:32:08 AM : Start Price: $14.54 AUXL Score: +18.52

Another crappy pharmaceutical company that will never earn a profit.